This Journal CME activity will examine the efficiency of tetrofosmin versus sestamibi achieved through shorter injection-to-imaging times through a systematic review of the literature.

This activity is targeted at imaging professionals and is intended to provide the latest information on clinical practice and cutting-edge scientific advances in nuclear cardiology and cardiac imaging.

After reading and reflecting upon this article in the Journal Nuclear Cardiology, the learner should be able to:

• Evaluate tracer kinetic differences in tetrofosmin versus sestamibi that affect image timing
• Assess individual optimal image times for high quality imaging with either tetrofosmin versus sestamibi

The purpose of this CME activity in the Journal of Nuclear Cardiology is to increase the learners’ competence in the application of nuclear cardiology strategies in clinical practice.

Evaluation Deadlines: AMA PRA Category 1 Credits™, ARRT Category A, and Participation Credits = July 15, 2022
The American Society of Nuclear Cardiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



Physicians: The American Society of Nuclear Cardiology designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Technologists: The American Society of Nuclear Cardiology is a recognized provider of continuing education credit for technologists. ASNC’s Continuing Education (CE) credit is accepted by both NMTCB and ARRT. This Journal-based activity has been approved for a maximum of 1 ARRT Category A credits for Technologists.

Release Date: July 16, 2021
Expiration Date: July 15, 2022